119th Congress
S. 229
DTC Act of 2025
- Introduced
- In committee
- Passed Senate
- Passed House
- To President
- Became law
- Sponsor
- Richard J. Durbin(D-IL)
- Introduced
- Jan 23, 2025
- Policy area
- Health
- Committees
- Senate Committee on Finance
- Official text
- Introduced in Senate · Congress.gov page
Cosponsors (9)
Original cosponsors (8)
- Angus S. King, Jr. (I-ME)
- Chuck Grassley (R-IA)
- Joni Ernst (R-IA)
- Peter Welch (D-VT)
- Richard Blumenthal (D-CT)
- Tammy Baldwin (D-WI)
- Tina Smith (D-MN)
- Tommy Tuberville (R-AL)
Added later (1)
- Cindy Hyde-Smith (R-MS) · Jan 28, 2025
Summary
Summary by the Congressional Research Service· describes the “Introduced in Senate” version
Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025
This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law.
Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage.
The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply.
Each violation of this requirement is subject to a civil penalty of not more than $100,000.
Roll-call votes
No recorded votes on this bill.
Actions
- Jan 23, 2025 · Senate
Read twice and referred to the Committee on Finance. (text: CR S337-338; Sponsor introductory remarks on measure: CR S337) - Jan 23, 2025
Introduced in Senate